- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2018
- Public Summary Document (PSD) November 2018 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2018 PBAC Meeting - Word
Pembrolizumab – November 2018
Pembrolizumab: Solution concentrate for I.V. infusion, 100 mg in 4 mL; Keytruda®
Last updated
1 March 2019